In September, Indian drug manufacturer Alembic received a tentative nod from the US Food and Drug Administration (FDA) to manufacture generic alogliptin as well as the alogliptin/metformin fixed-drug ...

One class of glucose-lowering agent may help lower the risk of kidney stones in adults with type 2 diabetes, a cohort study suggested. Adults who newly started on an SGLT2 inhibitor had a 31% lower ...

(HealthDay News) — From 2010 to 2014 there was an increase in use of diabetes medications, including sulfonylureas and dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors), among patients with ...

Patients with type 2 diabetes treated with sodium-glucose cotransporter-2 (SGLT-2) inhibitors have a significantly lower risk of developing dementia and Alzheimer's disease than those receiving ...

SaveHealth reports on managing type 2 diabetes through medications, lifestyle changes, and support, highlighting various treatment options, side effects, and newer therapies.

Reduction seen in recurrent nephrolithiasis events for those receiving SGLT-2 inhibitors vs GLP-1 RAs, DPP-4 inhibitors. HealthDay News — For patients with nephrolithiasis, sodium-glucose ...